Business
CHK1 Patent Update
CHK1 Patent Update.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 1888S Sareum Holdings PLC 22 September 2014 \n\n\n\n\n\n(AIM: SAR)\n\n\n22 September 2014\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or the \"Company\")\nCHK1 Patent Update\nSareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the European Office has issued notification of a grant of a patent for one of the inventions associated with the CHK1 cancer programme.\nThe patent* describes compounds that inhibit CHK1 kinase enzyme function and their potential to treat cancer, when administered alone or in combination with chemotherapy or radiotherapy. The CHK1 cancer programme is a co-development collaboration between the Cancer Research Technology Pioneer Fund, Sareum and BACIT Ltd. \nThis patent, which has also been granted in the USA, is part of a wide intellectual property estate which, if granted in its current form, would provide broad geographical protection for the CHK1 programme.\n* Patent No. EP2288601 \nSareum's CEO, Dr Tim Mitchell, commented: \"The intellectual property that underpins the CHK1 cancer programme continues to develop, protecting the asset and enhancing its commercial value\".\n\n\n\n\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\n\n\n\n\n\n\n\n\nSanlam Securities UK Limited (Nomad)\n\n\n\n\nSimon Clements / James Thomas\n\n\n020 7628 2200\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker)\n\n\n\n\n\n\n\nClaire Noyce / William Lynne\n\n\n0203 713 4581 / 4582\n\n\n\n\n\n\n\n\n\n\n\n\nThe Communications Portfolio (Media enquiries)\n\n\n\n\n\n\n\nAriane Comstive\[email protected]\n \n\n\n020 7536 2028\n\n\n\n\nNotes for editors: \nAbout Sareum Holdings plc\nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage. \nSareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.\nSKIL® (Sareum Kinase Inhibitor Library) is Sareum's...